SrasV1, PubMed, Checkpoint, bibRecord, 002C47

In vitro inhibition of SARS virus replication by human interferons.

Identifieur interne : 002C47 ( PubMed/Checkpoint ); précédent : 002C46; suivant : 002C48

In vitro inhibition of SARS virus replication by human interferons.

Auteurs : Helena Dahl [Suède] ; Annika Linde ; Orjan Stranneg Rd

Source :

Scandinavian journal of infectious diseases [ 0036-5548 ] ; 2004.

RBID : pubmed:15764169

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Cellules Vero, Humains, Interféron alpha (pharmacologie), Interféron bêta (pharmacologie), Protéines recombinantes, Réplication virale (), Virus du SRAS (), Virus du SRAS (physiologie).
MESH :
- pharmacologie : Antiviraux, Interféron alpha, Interféron bêta.
- physiologie : Virus du SRAS.
- Animaux, Cellules Vero, Humains, Protéines recombinantes, Réplication virale, Virus du SRAS.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Chlorocebus aethiops, Humans, Interferon alpha-2, Interferon-alpha (pharmacology), Interferon-beta (pharmacology), Recombinant Proteins, SARS Virus (drug effects), SARS Virus (physiology), Vero Cells, Virus Replication (drug effects).
MESH :
- chemical , pharmacology : Antiviral Agents, Interferon-alpha, Interferon-beta.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Humans, Interferon alpha-2, Recombinant Proteins, Vero Cells.

Abstract

Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.

DOI: 10.1080/00365540410021144
PubMed: 15764169

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002845
to stream PubMed, to step Curation: 002845

Links to Exploration step

pubmed:15764169

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro inhibition of SARS virus replication by human interferons.</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><nlm:affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Swedish Institute for Infectious Disease Control, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
</author>
<author><name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15764169</idno>
<idno type="pmid">15764169</idno>
<idno type="doi">10.1080/00365540410021144</idno>
<idno type="wicri:Area/PubMed/Corpus">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002845</idno>
<idno type="wicri:Area/PubMed/Curation">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002845</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C47</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro inhibition of SARS virus replication by human interferons.</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><nlm:affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Swedish Institute for Infectious Disease Control, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
</author>
<author><name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</author>
</analytic>
<series><title level="j">Scandinavian journal of infectious diseases</title>
<idno type="ISSN">0036-5548</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Interferon-beta (pharmacology)</term>
<term>Recombinant Proteins</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Vero Cells</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Interféron bêta (pharmacologie)</term>
<term>Protéines recombinantes</term>
<term>Réplication virale ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Interferon-beta</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Interféron bêta</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Recombinant Proteins</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Protéines recombinantes</term>
<term>Réplication virale</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15764169</PMID>
<DateCompleted><Year>2005</Year>
<Month>04</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-5548</ISSN>
<JournalIssue CitedMedium="Print"><Volume>36</Volume>
<Issue>11-12</Issue>
<PubDate><Year>2004</Year>
</PubDate>
</JournalIssue>
<Title>Scandinavian journal of infectious diseases</Title>
<ISOAbbreviation>Scand. J. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro inhibition of SARS virus replication by human interferons.</ArticleTitle>
<Pagination><MedlinePgn>829-31</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dahl</LastName>
<ForeName>Helena</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Linde</LastName>
<ForeName>Annika</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Strannegård</LastName>
<ForeName>Orjan</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Scand J Infect Dis</MedlineTA>
<NlmUniqueID>0215333</NlmUniqueID>
<ISSNLinking>0036-5548</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>3</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>3</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15764169</ArticleId>
<ArticleId IdType="pii">VVV0LF7WY2FK3JER</ArticleId>
<ArticleId IdType="doi">10.1080/00365540410021144</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suède</li>
</country>
<region><li>Svealand</li>
</region>
<settlement><li>Stockholm</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
<name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</noCountry>
<country name="Suède"><region name="Svealand"><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C47 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002C47 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:15764169
   |texte=   In vitro inhibition of SARS virus replication by human interferons.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:15764169" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

In vitro inhibition of SARS virus replication by human interferons.

In vitro inhibition of SARS virus replication by human interferons.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki